Calaspargase (Asparlas)
General information
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase. This product provides for a longer interval between doses compared to other available pegaspargase products.
Route: IV, IM
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 2018-12-20: Initial approval as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years. (Based on COG AALL07P4)
Patient Drug Information
Also known as
- Generic name: calaspargase pegol-mknl
- Brand name: Asparlas